Get the Stockscreener App
7.04
19.52%
1.15
After Hours:
1.90
-5.14
-73.01%
Exicure Inc stock is traded at $7.04, with a volume of 4.25M.
It is up +19.52% in the last 24 hours and down -28.67% over the past month.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.
See More
Previous Close:
$5.89
Open:
$6.31
24h Volume:
4.25M
Relative Volume:
258.74
Market Cap:
$59.01M
Revenue:
$28.83M
Net Income/Loss:
$-13.34M
P/E Ratio:
-4.6316
EPS:
-1.52
Net Cash Flow:
$-7.49M
1W Performance:
+8.31%
1M Performance:
-28.67%
6M Performance:
-48.50%
1Y Performance:
+340.00%
1-Day Range:
$6.01
$8.36
1-Week Range:
$5.42
$8.36
52-Week Range:
$1.44
$36.00
Exicure Inc Stock (XCUR) Company Profile
Name
Exicure Inc
Sector
Industry
Phone
847-673-1700
Address
2430 N. HALSTED ST., CHICAGO, IL
Compare XCUR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.625 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
0.3702 | 544.73M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.40 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1441 | 316.76M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
2.77 | 118.42M | 0 | 0 | 0 | 0.00 |
|
DAVEW
Dave Inc
|
1.81 | 0 | 0 | 0 | 0 | 0.00 |
Exicure Inc Stock (XCUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-18-20 | Initiated | BMO Capital Markets | Outperform |
| Nov-20-19 | Initiated | Guggenheim | Buy |
Exicure Inc Stock (XCUR) Latest News
Exicure (NASDAQ:XCUR) Stock Price Down 5.8% – Here’s Why - Defense World
What's Going On With Exicure Shares Monday? - MSN
Trading (XCUR) With Integrated Risk Controls - news.stocktradersdaily.com
XCURExicure, Inc. Reports Full Year 2024 Financial Results - mx.advfn.com
Exicure faces Nasdaq non-compliance notice By Investing.com - Investing.com South Africa
(XCUR) Trading Report - news.stocktradersdaily.com
Exicure Receives Nasdaq Delinquency Notification - TipRanks
Exicure faces Nasdaq non-compliance notice - Investing.com Australia
Exicure (XCUR) Faces Nasdaq Non-Compliance Due to Delayed Report - GuruFocus
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q | XCUR Stock News - GuruFocus
Exicure Receives Noncompliance Notice From Nasdaq - marketscreener.com
Exicure (XCUR) Faces Nasdaq Non-Compliance Due to Delayed Report | XCUR Stock News - GuruFocus
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q - Business Wire
Exicure (NASDAQ:XCUR) Trading Down 4.5% – Here’s Why - Defense World
Exicure (XCUR) Is Paying a $5.6M Settlement to Investors — Here’s How to Get Your Share - TradingView
Exicure Delays 10-Q Filing Amid Acquisition - TipRanks
(XCUR) Investment Analysis and Advice - news.stocktradersdaily.com
Exicure enters strategic convertible bond agreement By Investing.com - Investing.com Nigeria
Exicure Enters Convertible Bond Agreement with Subsidiary - TipRanks
Exicure enters strategic convertible bond agreement - Investing.com
Exicure concludes subject enrolment in trial of GPC-100 for multiple myeloma - Yahoo Finance
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant | XCUR Stock News - GuruFocus
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant - Business Wire
Geode Capital Management LLC Purchases Shares of 12,645 Exicure, Inc. (NASDAQ:XCUR) - Defense World
Exicure, Inc. (NASDAQ:XCUR) Sees Significant Drop in Short Interest - Defense World
Investors Can Still File Late Claims for Exicure $5.6M Settlement Payouts - TradingView
Why Exicure Inc. (XCUR) Soared on Monday - MSN
How To Trade (XCUR) - news.stocktradersdaily.com
10 Micro-, Small-Cap Companies Lead Monday’s Charge - Insider Monkey
Exicure, Inc. (NASDAQ:XCUR) Sees Large Drop in Short Interest - Defense World
Exicure Close to Finishing Patient Recruitment in Phase 2 Study of GPC-100 in Multiple Myeloma - MarketScreener
Exicure appoints new independent accounting firm By Investing.com - Investing.com India
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma - BioSpace
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study o - GuruFocus
Exicure appoints new independent accounting firm - Investing.com Australia
Breakthrough: New Multiple Myeloma Treatment Achieves Perfect Success Rate in Trial - Stock Titan
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML) - BioSpace
How to Take Advantage of moves in (XCUR) - news.stocktradersdaily.com
Eli Lilly and Company (NYSE:LLY) and Exicure (NASDAQ:XCUR) Head to Head Analysis - Defense World
Exicure, Inc. (NASDAQ:XCUR) Sees Significant Growth in Short Interest - The AM Reporter
Short Interest in Exicure, Inc. (NASDAQ:XCUR) Grows By 58.5% - Defense World
Wednesday’s Insider Moves: Top Buys and Sells in US Stocks - Investing.com India
Wednesday’s Insider Moves: Top Buys and Sells in US Stocks By Investing.com - Investing.com UK
Major Investment Alert: HiTron Systems Inc. Boosts Stake in Exicure! - TipRanks
HiTron Systems acquires $8.7 million in Exicure stock By Investing.com - Investing.com Canada
HiTron Systems acquires $8.7 million in Exicure stock - Investing.com
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Exicure, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm - Business Wire
Exicure Inc Stock (XCUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Exicure Inc Stock (XCUR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DGP Co., Ltd. | 10% Owner |
Sep 12 '24 |
Buy |
3.00 |
237,223 |
711,669 |
849,223 |
0.78%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):